<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

CP 471474

產(chǎn)品貨號

Axon 2104 CAS [210755-45-6] MF C16H17FN2O5SMW 368.38 Purity: 99% Soluble in DMSO Description CP 471474 is a matrix metalloprotease inhibitor with sub-nanomolar affinity for MMP-2 and 13 among a broad range of MMPs (IC50: 1170, 0.7, 16, 13, 0.9 for MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 respectively). It attenuates early left ventricular dilation after experimental myocardial infarction in mice. Similarly, CP-471474 attenuated both the early inflammatory response and the emphysematous lesions induced by chronic exposure to cigarette smoke in guinea pigs. References Certificates Categories Extra info LA Reiter et al. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395. ? LE Rohde et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 99, 3063-3070.? ? M Selman et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 2003, 123, 1633-1641.? Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology Miscellaneous Pain & Inflammation EC 3.4.24.24 MMP Pfizer Licensed Products MMP inhibitor Chemical name 2-(4-(4-fluorophenoxy)phenylsulfonamido)-N-hydroxy-2-methylpropanamide Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [210755-45-6] Order Size Unit Price Stock 10 mg €95.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

CP 471474

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2104

CAS [210755-45-6]

MF C16H17FN2O5S
MW 368.38

Purity: 99%
Soluble in DMSO

CP 471474

Description

CP 471474 is a matrix metalloprotease inhibitor with sub-nanomolar affinity for MMP-2 and 13 among a broad range of MMPs (IC50: 1170, 0.7, 16, 13, 0.9 for MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 respectively). It attenuates early left ventricular dilation after experimental myocardial infarction in mice. Similarly, CP-471474 attenuated both the early inflammatory response and the emphysematous lesions induced by chronic exposure to cigarette smoke in guinea pigs.

LA Reiter et al. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395.

LE Rohde et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 99, 3063-3070.?

M Selman et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 2003, 123, 1633-1641.?

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology Miscellaneous Pain & Inflammation EC 3.4.24.24 MMP Pfizer Licensed Products

MMP inhibitor

Chemical name

2-(4-(4-fluorophenoxy)phenylsulfonamido)-N-hydroxy-2-methylpropanamide

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[210755-45-6]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>